| Year |
Citation |
Score |
| 2016 |
Skalweit MJ, Li M. Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms. Drug Design, Development and Therapy. 10: 3013-3020. PMID 27703329 DOI: 10.2147/Dddt.S110193 |
0.367 |
|
| 2016 |
Dumford DM, Skalweit MJ. Antibiotic-Resistant Infections and Treatment Challenges in the Immunocompromised Host. Infectious Disease Clinics of North America. 30: 465-489. PMID 27208768 DOI: 10.1016/J.Idc.2016.02.008 |
0.339 |
|
| 2016 |
Skalweit MJ. An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS. International Journal of Std & Aids. 27: 1346-1349. PMID 27074792 DOI: 10.1177/0956462416643852 |
0.362 |
|
| 2015 |
Skalweit MJ. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Design, Development and Therapy. 9: 2919-25. PMID 26082619 DOI: 10.2147/Dddt.S61436 |
0.397 |
|
| 2015 |
Skalweit MJ, Li M, Taracila MA. Effect of asparagine substitutions in the YXN loop of a class C β-lactamase of Acinetobacter baumannii on substrate and inhibitor kinetics. Antimicrobial Agents and Chemotherapy. 59: 1472-7. PMID 25534745 DOI: 10.1128/Aac.03537-14 |
0.359 |
|
| 2015 |
Khatri A, Skalweit MJ. A rare case of immune reconstitution inflammatory syndrome presenting as secondary syphilis International Journal of Std and Aids. 26: 749-751. PMID 25311145 DOI: 10.1177/0956462414553013 |
0.31 |
|
| 2013 |
Skalweit MJ, Li M, Conklin BC, Taracila MA, Hutton RA. N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam. Antimicrobial Agents and Chemotherapy. 57: 1596-602. PMID 23318801 DOI: 10.1128/Aac.01334-12 |
0.356 |
|
| 2012 |
Li M, Conklin BC, Taracila MA, Hutton RA, Skalweit MJ. Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance. Antimicrobial Agents and Chemotherapy. 56: 5678-86. PMID 22908166 DOI: 10.1128/Aac.00711-12 |
0.4 |
|
| 2012 |
Papp-Wallace KM, Senkfor B, Gatta J, Chai W, Taracila MA, Shanmugasundaram V, Han S, Zaniewski RP, Lacey BM, Tomaras AP, Skalweit MJ, Harris ME, Rice LB, Buynak JD, Bonomo RA. Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrobial Agents and Chemotherapy. 56: 5687-92. PMID 22908165 DOI: 10.1128/Aac.01027-12 |
0.387 |
|
| 2012 |
Ke W, Rodkey EA, Sampson JM, Skalweit MJ, Sheri A, Pagadala SR, Nottingham MD, Buynak JD, Bonomo RA, van den Akker F. The importance of the trans-enamine intermediate as a β-lactamase inhibition strategy probed in inhibitor-resistant SHV β-lactamase variants. Chemmedchem. 7: 1002-8. PMID 22438274 DOI: 10.1002/Cmdc.201200006 |
0.342 |
|
| 2010 |
Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA. Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2. Biochemistry. 49: 1014-23. PMID 19938877 DOI: 10.1021/Bi9015549 |
0.379 |
|
| Show low-probability matches. |